Perspective: COVID-19, implications of nasal diseases and consequences for their management - 22/07/20
Doi : 10.1016/j.jaci.2020.04.030
Li Jian, MD, PhD a, Wei Yi, PhD a, Nan Zhang, MD, PhD b, Weiping Wen, MD, PhD a, Olga Krysko, PhD b, Woo-Jung Song, MD, PhD c, Claus Bachert, MD, PhD a, b, d, ⁎ 
a First Affiliated Hospital, Sun Yat-sen University, International Airway Research Center, Guangzhou, China
b Upper Airways Research Laboratory and Department of Oto-Rhino-Laryngology, Ghent University, Ghent, Belgium
c Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
d Division of ENT Diseases, CLINTEC, Karolinska Institute, University of Stockholm, Stockholm, Sweden
∗Corresponding author: Claus Bachert, MD, PhD, First Affiliated Hospital, Sun Yat-sen University, International Airway Research Center, 58 Zhong Shan Er Lu, 510080 Guangzhou, China.First Affiliated HospitalSun Yat-sen UniversityInternational Airway Research Center58 Zhong Shan Er LuGuangzhou510080China
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Key words : SARS-CoV-2, COVID-19, chronic rhinosinusitis, allergy, corticosteroids, biologics
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: C. Bachert acted as speaker and member of advisory boards for Sanofi-Aventis, Novartis, Glaxo, Astra-Zeneca, Stallergenes, ALK, and Mylan. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2020
Publié par Elsevier Masson SAS.
Vol 146 - N° 1
P. 67-69 - juillet 2020 Retour au numéro
Article précédent
- COVID-19 diagnostic process in mainland China: The math beyond pneumonia
- Feng Wu, Weishan Huang
- Will environmental impacts of social distancing due to the pandemic caused by SARS-CoV-2 decrease allergic disease?
- Valentin Navel, Frédéric Chiambaretta, Frédéric Dutheil
Bienvenue sur EM-consulte, la référence des professionnels de santé.